Taxotere

TABLE 1. Effects of ACE Inhibition Alone and the Addition of NEP Inhibition to ACE Inhibition on Peptide Levels. Patients A total of 41 patients were enrolled on this study from the allogeneic transplantation program of Dana-Farber Cancer Institute Brigham and Women's Hospital between September 2000 and June 2002. The majority of patients n 36 ; had unrelated donors and the rest had.

Ducting pathway is not along any of the known nerve pathways but rather it is suggested that the wave of dilatation is propagated along the smoothmuscle cells of the media. The author concludes that this primitive, peripheral-conducting mechanism is important in the regulation of local blood supply and is independent of central nervous system control. Department of Medical Oncologv. School of Medicine, University of Crete, 2 First Department of Pulmonary Diseases, Sotiria'General Hospital of Athens, 3Department ofPulmonary Diseases, School of Medicine, University of Athens, 'Sotiria' General Hospital of Athens, ''Second Department of Pulmonary Diseases, 'Sismanoglion' General Hospital of Athens, 5First Department of Medical Oncologv. Agios Savva.s'Anlicancer Hospital of Athens, 6 Department of Bwstatistics, School of Medicine, University of Crete. Greece ' See page 469 for a list ofparticipating centers and investigators.

Solution for injection solution for injection solution for injection caps. caps. film-coated tab. film-coated tab. sol.oleosa tab. tab. tab. sir. herbal tea herbal tea.
The results obtained with combinations of taxotere and various chemotherapeutic agents, such as cyclophosphamide alkylating agent ; , 5-fluorouracil antimetabolite ; , etoposide semisynthetic podophyllotoxin agent ; and vincristine vinca alkaloid ; , the combinations being used at their optimum dose, are given as examples in the following tables and tazorac. Xeloda and taxotere is the first and only combination treatment to improve a women's chance or survival compared to taxotere alone. Fanjakan-dranomasina "melayu" indrindra, niseho tamin'ny taonjato faha-7 ary rava tamin'ny taonjato-faha-13. Saiky ny morontsiraky Asia Atsimo-Atsinanana manontolo, ary indrindra moa ny an'i Indonesia andrefana sy Malaysia dia teo ampelantanan'i Srivijaya izay angamba koa nitana tobim-pivarotana "comptoir" ; tany Afika atsinanana sy Madagasikara. I Srivijaya koa ohatra no nanangana ny "candi" na tempoly-fasan'andrian'i Borobudur any Jawa, izay ekena fa "monument bouddhiste" lehibe indrindra eran-tany.Cf. O.W.Wolters, Early Indonesian Commerce : A Study of the Origins of Srivijaya. New York : Cornell UP, 1967 sy The Fall of Srivijaya in Malay History, Kuala Lumpur ; Oxford UP, 1970 ; Bambang Sumadio, ed. "Jaman Kuno", Sejarah Nasional Indonesia II, Jakarta : Balai Pustaka, 1977 ; Nia Kurnia Sholifat Irfan, Kerajaan Sriwijaya, Jakarta : Girimukti Pasaka, 1983. 2 Cf. M.Kaltenmark, "Le dompteur des flots", Han-Hiue, Bulletin du Centre d'Etudes Sinologiques de Pekin, III, 1-2, 1948, tkl. 86-91. 3 P.K.Benedict, Austro-Thai Language and Culture, with a glossary of roots, New Haven : HRAF Press, 1975, tkl. 336 and telithromycin.
Universal Serial Bus HID Usage Tables Menu Pick Menu Up Menu Down Menu Left Menu Right Menu Escape Menu Value Increase OSC Picks an item from an on-screen menu. OSC Moves the selection up in a device-displayed menu. OSC Moves the selection down in a device-displayed menu. OSC Moves the selection left in a device-displayed menu. OSC Moves the selection right in a device-displayed menu. OSC Backs up a level in the on-screen menu system. OSC Increments the value of the currently selected menu item. For example, after using a menu to select a volume control, the user can modify the volume level using this control. OSC Decrements the value of the currently selected menu item.
At the end of 1998, the directors gave the OFDT priority lines of work for the years 1999-2001 that were confirmed at the end of 2001 for 2002. These were as follows: The OFDT's field of competence will henceforth cover all psychoactive substances, namely drugs, alcohol, tobacco and psychotropic medicaments. Its monitoring must therefore be progressively extended from the field of illicit drugs alone to cover all psychoactive substances. The OFDT, as French focal point of the REITOX network, will fulfil the obligations described in the REITOX work programme as defined each year by the EMCDDA. It will also play an active part in other work of the EMCDDA that comes within the priority lines of work defined above. MONITORING AND IMPROVEMENT OF INDICATORS In order to provide the most exact measurement possible of the incidence of drugs and drug use, the OFDT will analyse the existing indicators and suggest suitable measures to improve the quality and reliability of sources within the various ministries and other organisations. If gaps are identified, the OFDT will initiate work to fill them. TREND MONITORING The objective is to have real-time knowledge of the trends in consumption, methods and their consequences and the nature of products in circulation. A dual system will therefore be established: a "sentinel surveillance network" to monitor trends in the contexts of use, making use both of the existing arrangements and of ad hoc "sensors" TREND project ; and a system for collecting analyses of products in circulation SINTES project ; . Such a system will also make it possible to respond to the demands of the joint European action on synthetic drugs. EVALUATION OF PUBLIC POLICIES In the field of evaluation, the OFDT is charged with: defining an overall framework for the evaluation of public policies, developing methodologies and know-how based, where appropriate, on work in other countries and establishing and following to their conclusion evaluations of public actions and spot and short term studies falling within this general plan. ASSESSMENT Within its field of competence, the OFDT will respond to requests for assessment or intervention from the main French and international bodies. The OFDT could be called on as an expert by local or national players seeking validation of an observation method. DISTRIBUTION AND PROMOTION The OFDT must be in a position to distribute and promote its work, including that carried out outside its field of competence, amongst a public of "specialists" decision-makers, informed professionals, researchers etc. ; . It must become a point of reference for those seeking information on these topics. The OFDT will periodically draw up an assessment of the incidence of drugs and their use by publishing a report on indicators and trends. This note relates the implementation of its lines of work and temodar.

Design 2: This design gives the Herceptin of Lapatanib during the taxanes portion of the adjuvant chemo. LVEF 50%. It uses Taxol x 12 wks either with weekly Herceptin x 12 wks then q 3 wks x 40 vs weekly Taxol x 12wks + Lapatanib x 52 wks vs weekly Taxol x 12 with Herceptin x12 then wash out x 6 wks then Lapatanib x 34 wks vs weekly Taxol x 12 + Herceptin + lapatanib followed by H + wks NOTE: Design 1 allows adriamycin Taxol or taxotere combination as initial adjuvant chemotherapy and then you can get Herceptin lapatanib post chemo. Design 2 allows AC first then you can go on to Taxol + - H or both 8000 pts with 4000 in USA thru NCCTG. Phase II fulvestrant + BV for metastatic ER + BC. Just approved by CIRB so it will opening to the group soon. NOTE: TAILORx trial may be modified to allow PBI patients to be enrolled. But of course these patients could not come from B-39 since NSABP won't allow this ; . She pushed the cooperation with ECOG on E2104: THIS IS NOT YET activated This is a trial for N + resected BC. The time frame that the drug is available to the tissues, and may have a plausible role in the pathology of depression or the mechanism of action of current antidepressive agents and tenex. YASER KHALIGHI, PARVIZ MOIN, FRANK HAM, Center for Turbulence Research, Stanford University -- The goal of present work is to study the nature of broadband noise generated by flow of practical interest. With this objective, flow over trailing of a hydrofoil at chord Reynolds number of 1.9 Million is considered. This flow configuration includes practical complexities such as turbulent boundary layers with pressure gradients, turbulent wake and irregular geometry. An incompressible formulation with 2nd order, non-dissipative numerical scheme is applied to calculate the hydrodynamic noise sources. Flow scales are fully resolved in the boundary layers and in the vicinity of the trailing edge resulting in a 100M grid point unstructured computational domain. Lighthill's acoustics analogy with a boundary element formulation is applied to accurately predict the propagation and scattering of acoustics waves. The large unstructured grid is generated by the recursive refinement of a coarser grid, facilitating solution verification of both the flow and noise calculation by a grid convergence study. The results will be validated by comparison to hot-wire flow measurements from Michigan State University as well as acoustics measurements from an anechoic chamber at Notre Dame University.

Although the 4th independent external review was established by JCB in February 2005, the decision to undertake it had been made by JCB as early as June 2003 at its 26th meeting. JCB had requested an early commencement of the Fourth External Review in order to gain maximum benefit from the review for the preparation of TDR's Strategy for the period of 2006-2011. However, this was delayed partly because of the change of the Programme director and the ongoing discussions in the JCB on a ten-year vision for TDR. The terms of Reference were revised and finalized in 2004. The purpose of the Fourth External Review was "to assess the overall relevance, appropriateness, adequacy and efficiency of TDR in relation to its current objectives, strategic approaches, and stated values see the Strategy 2000-2005 document ; . To achieve this, the Review will include a broad Programme assessment, which will look at all of the Programme's relevant aspects." 22 The 4th External Review Committee ERC ; was also asked to be prospective, looking at "the role of TDR in the broader international research, control, and institutional environment, taking into account the nature and values of the Programme and its comparative advantages" and to " take into account findings from related studies" including: a Management Review presented to JCB 27 ; in June 2004 ; a review of the governance of TDR conducted by a JCB Sub-Committee and presented to JCB 27 ; in June 2004 ; World Bank Approaches to Global Programmes: An Independent Evaluation Phases I and II ; completed, a brief summary of findings presented to JCB 27 ; by the Bank Impact Evaluation for TDR: Feasibility and Approaches C. Michaud and M. Reich, May 2005; study commissioned by TDR; revised in December 2005 ; Options for Positioning and Role of TDR in the Current and Future Research Environment C. Michaud and M. Reich, presented to STAC in February 2005, and subsequently revised ; . The 4th review is meant look back at the past 5 to 6 years, following on the Third External Review, with emphasis on the period from 2000, which was the start of the TDR's Strategy for 2000-2005. The review was specifically asked to take a prospective view over the next 10 years, i.e. up to 2015. "For the next strategic period, different scenarios should be considered, including, for example, resource increases and a broader mandate." In June 2005, Professor Abdallah Daar, chair of the 4th External Review Committee, gave the JCB an overview of the work undertaken to that date. The presentation was received very well and the ERC was thanked for its efforts. The JCB brought up a number of suggestions and ideas for consideration by the ERC when pursuing its work, including: an agreement that and teniposide. Patients treated with the taxotere carboplatin combination also reported less significant neurotoxicity symptoms such as tingling in the hands and numbness in fingers or toes during treatment compared to those treated with paclitaxel carboplatin p 1 ; and at six months post-randomization p 1 ; , with differences maintained at least 14 months from randomisation. In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme, and its metabolism can be inhibited by CYP3A4 inhibitors, such as ketoconazole, erythromycin, troleandomycin, and nifedipine. Based on in vitro findings, it is likely that CYP3A4 inhibitors and or substrates may lead to substantial increases in docetaxel blood concentrations. No clinical studies have been performed to evaluate this finding see PRECAUTIONS ; . CLINICAL STUDIES Breast Cancer The efficacy and safety of TAXOTERE have been evaluated in locally advanced or metastatic breast cancer after failure of previous chemotherapy alkylating agent-containing regimens or anthracycline-containing regimens ; . Randomized Trials In one randomized trial, patients with a history of prior treatment with an anthracyclinecontaining regimen were assigned to treatment with TAXOTERE 100 mg m2 every 3 weeks ; or the combination of mitomycin 12 mg m2 every 6 weeks ; and vinblastine 6 mg m2 every 3 weeks ; . 203 patients were randomized to TAXOTERE and 189 to the comparator arm. Most patients had received prior chemotherapy for metastatic disease; only 27 patients on the TAXOTERE arm and 33 patients on the comparator arm entered the study following relapse after adjuvant therapy. Three-quarters of patients had measurable, visceral metastases. The primary endpoint was time to progression. The following table summarizes the study results See Table 1 ; . Table 1-Efficacy of TAXOTERE in the Treatment of Breast Cancer Patients Previously Treated with an Anthracycline-Containing Regimen Intent-to-Treat Analysis ; Efficacy Parameter Docetaxel Mitomycin p-value Vinblastine n 203 ; n 189 ; Median Survival 11.4 months 8.7 months Risk Ratio * , Mortality Docetaxel: Control ; 0.73 p 0.01 Log Rank 95% CI Risk Ratio ; 0.58-0.93 Median Time to 4.3 months 2.5 months Progression Risk Ratio * , Progression p 0.01 Docetaxel: Control ; 0.75 Log Rank 95% CI Risk Ratio ; Overall Response Rate Complete Response Rate 0.61-0.94 28.1% 3.4% p 0.0001 Chi Square and tenofovir.

Pregnancy and breast-feeding: taxotere has been shown to cause harm to the fetus. As good as a play. Then everybody goes to lunch -- swells and selectors, Germans and Paddies, natives and immigrants, a good many of them, too, and there was eating and drinking and speechifying till all was blue. By and by the auctioneer looks at his watch. He'd had a pretty good tuck-in himself, and they must get to business. Father opened his eyes at the price the first pen brought, all prime young bullocks, half fat most of them. Then they all went off like wildfire; the big men and the little men bidding, quite jealous, sometimes one getting the lot, sometimes another. One chap made a remark about there being such a lot of different brands; but Starlight said they'd come from a sort of depot station of his, and were the odds and ends of all the mobs of store cattle that he'd purchased the last four years. That satisfied 'em, particularly as he said it in a careless, fierce way which he could put on, as if it was like a man's - impudence to ask him anything. It made the people laugh; I could see that. By and by we comes to the imported bull. He was and tequin. The presenting manifestation in 5 patients 11% ; . The neuropathy was associated with alterations of the endoneurial microvessels, but necrotizing vasculitis was not seen.35 Central nervous system disease in patients with SS is believed to be very rare, but its incidence is controversial. 36 In a study of 30 women with primary SS, 14 46% ; had sensorineural hearing loss, which was significant in 5. Hearing loss in these patients was correlated with the presence of anticardiolipin antibodies, suggesting an underlying autoimmune cause.4 Hematologic Oncologic Involvement Compared with age-, sex-, and race-matched controls, patients with SS in one study had a 44 times higher relative risk of lymphoma, and clinically identifiable lymphoma occurs in approximately 5% of patients with SS.37 Malignant lymphoproliferation may be present initially or may develop later in the disease. An essential process in the transition from the autoimmune state to non-Hodgkin lymphoma is monoclonality, and monoclonal B-cell expansion occurs in some patients with SS, arising mainly from exocrine glands and less frequently from visceral organs or lymph nodes. 38 Monoclonal B-cell proliferation may initially present as Waldenstro m macroglobulin emia.37 Patients with SS having risk factors for progression to lymphoma Table 1 ; should be closely monitored. Those with persistent gland enlargement, purpura, low levels of C4, and monoclonal cryoglobulinemia are at increased risk.1, 7, 40 Most lymphomas in patients with SS are of B-cell lineage and are of low- or intermediate-grade malignancy. These lymphomas are usually localized in extranodal areas such as the salivary glands, gastrointestinal tract, thyroid gland, lung, kidney, or orbit. Localized, lowgrade lymphoma affecting exocrine glands can be managed by watchful waiting; disseminated lymphoma may be treated with combination chemotherapy.1. Our first encouraging results using docetaxel in paclitaxel pretreated MBC patients Abstract book 25th ESMO Congress, Hamburg 2000 ; have had induced us to establish this as a standard "next step" chemotherapy in treatments of our MBC patients. Up to August 2001, 27 patients were treated in this way. Pretreatment included adjuvant CMF therapy and anthracycline as the first-line treatment for metastatic disease. Four patients received PCMF as the second-line and three patients received MV protocol as the third-line chemotherapy. All patients were treated with paclitaxel as monotherapy or in combination with cisplatinum ; as well. After the treatment failed, all patients received docetaxel Taxotere ; as monotherapy 100 mg m2 1h IV day 1, q 3 weeks ; . Adequate premedication was applied. Six patients were treated on outpatient's basis. Median age was 51 38-62 ; years. Thirteen 48.1% ; patients were premenopausal and fourteen 51.9% ; postmenopausal. Twentythree 85.2% ; patients had two or more metastatic lesions. With eleven 40.7% ; patients liver was dominant metastatic site. All patients were evaluable for response and toxicity. A total of 131 chemotherapy courses were administered, with a median of 4 cycles per patient range 3-6 ; . Response so far included two 7.4% ; CR and fourteen 51.9% ; PR for ORR of 59.3% 95%CI 56.6-85.4 ; . SD occurred in another four 14.8% ; patients accounting for a tumor control rate of 74.1%. In seven 25.9 % ; patients PD was observed. Best response was seen in patients with liver metastases 54 % ; . Neutropenia grade 3 was observed in five 18.5 % ; and grade 4 in two 7.4 % ; patients. None of patients had a febrile neutropenia. Grade 3 thrombocytopenia developed in four 14.8 % ; patients. Grade 4 was not observed. Nonhematological toxicity was mild. Docetaxel is active in anthracycline- and paclitaxel pretreated MBC, resulting in an ORR of 59.3% and tumor control rate of 74.1%. This treatment was generally well tolerated and can be safely used on outpatient basis. Our data confirm an incomplete cross-resistance between docetaxel and paclitaxel and terfenadine. T H E THE RESEARCH Now we would like to present a few selected results of the microanalysis of the 20-minute videorecordings of 30 out of 41 observed ; Czech children that are available at the moment, after they were processed by the computer system Interact. Note 8: It should be noted that this system is no longer used in current research 2004-2006 ; for carrying out observations of children aged 12, 24 and 36 months in a family environment ; because it showed itself as unsatisfactory. It was originally created for the comparison of the early mother-child interaction by H. Papousek and M. Papouskov, where fewer categories were used and where the child was secured in a chair. Our research, however, requires the use of a large number of subcategories and that the child be free to move and be of various ages. The author of the computer program V. I. P. created by our research group is T. Hrdlicka. Table I. EGCG treatment decreases BrdU incorporation and induced apoptosis in the skin of K6 ODC transgenic mice Percent caspase 3-positive cells Normal littermate skin Water 0 EGCG 0 K6 ODC transgenic skin Water 0 EGCG 0.45 0.26 BrdU incorporation and teriparatide and taxotere. We found that patients treated with taxotere in the second-line setting had a significant improvement in their survival, said frank fossella, md, medical director, thoracic medical oncology multidisciplinary care center at the university of texas, d.
Source: Economic Commission for Latin America and the Caribbean ECLAC ; , on the basis of the Export-Import Bank of Korea, Overseas Direct Investment Statistics Yearbook. 2005 and Overseas Direct Investment Statistics Yearbook, 2006 and thalidomide.

In 2002, the number of calls received was lower than in previous years due to: February and March - reduced hours of operation due to staffing shortages. March to August - the telecommunications provider inappropriately diverted some Victorian calls to the New South Wales Poisons Information Centre. IN THE MATTER OF A DISCIPLINARY HEARING PURSUANT TO SECTIONS 20 AND 24 OF BY-LAW NO. 1 OF THE MUTUAL FUND DEALERS ASSOCIATION OF CANADA.
2003 Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata Wang, H., Mahadevappa, M., Yamamoto, K., Wen, Y., Chen, B., Warrington, J.A., Polan, M.L. Fertility and Sterility 80 2 ; , pp. 266-276 2003 Identification of genes up-regulated in urothelial tumors: The 67-kd laminin receptor and tumor-associated trypsin inhibitor Diggle, C.P., Cruickshank, S., Olsburgh, J.D., Pellegrin, S., Smith, B., Banks, R.E., Selby, P.J., . ; , Harnden, P. American Journal of Pathology 163 2 ; , pp. 493-504 2003 Oral cancer: Reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management Nagpal, J.K., Das, B.R. Oral Oncology 39 3 ; , pp. 213-221 2003 Gene discovery in oral squamous cell carcinoma through the Head and Neck Cancer Genome Anatomy Project: Confirmation by microarray analysis Leethanakul, C., Knezevic, V., Patel, V., Amornphimoltham, P., Gillespie, J., Shillitoe, E.J., Emko, P., . ; , Gutkind, J.S. Oral Oncology 39 3 ; , pp. 248-258 2003 Genomic dissection for characterization of cancerous oral epithelium tissues using transcription profiling Hwang, D., Alevizos, I., Schmitt, W.A., Misra, J., Ohyama, H., Todd, R., Mahadevappa, M., . ; , Stephanopoulos, G. Oral Oncology 39 3 ; , pp. 259-268 2003 Gene expression profile in oral squamous cell carcinomas and matching normal oral mucosal tissues from black Africans and white Caucasians: The case of the Sudan vs. Norway Ibrahim, S.O., Aars?ther, N., Holsve, M.K., Kross, K.W., Heimdal, J.H., Aarstad, J.H., Liavaag, P.G., . ; , Vasstrand, E.N. Oral Oncology 39 1 ; , pp. 37-48.
33. Esmaeli B, Booser D, Ahmadi MA, et al: Canalicular stenosis is the mechanism for excessive tearing in patients on weekly docetaxel. Proc Soc Clin Oncol 20: 45a, 2001 abstr 177 ; 34. Ahmadi MA, Esmaeli B: Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. Arch Ophthalmol 119: 1802-1804, 2001 Pestalozzi BC, Brignoli S: Trastuzumab in CSF. J Clin Oncol 18: 2350-2351, 2000 letter ; 36. Burris HA III: Docetaxel Taxotere ; plus trastuzumab Herceptin ; in breast cancer. Semin Oncol 28: 38-44, 2001 suppl 3.

To as "The Aventis Group" ; and covered by Medicare Part B include, but may not be limited to: Anzemet dolasteron mesylate ; , Bioclate antihemo factor viii ; , Gammar immune globulin ; , Helixate antihemo factor viii ; , Humate-P antihemo factor viii ; , Mononine antihemo factor ix complex ; , Monoclate-P antihemo factor viii ; and Taxotere docetaxel ; . Baxter 68. Defendant Baxter International Inc. "Baxter" ; is a Delaware corporation with and tazorac. Positive cells for 0.05 and 0.1 mg kg Nit, respectively; Fig. 2, B and C]. NTS-C2. This nucleus showed a distinctive regional segregation in the pattern of cFos immunostaining. The rostra1 portion was negative with all treatments, whereas the caudal portion, anterior to the area postrema, showed a minimal responseto iv saline 4 + 3 cells; Fig. 3D ; , but demonstrated a significant responseto iv Nit. Nit stimulated the expression of cFos immunoreactivity maximally after the low dose [60 + 12 P 0.01 ; and 62 + 8 cFos-positive cells for 0.05 and 0.1 mg kg Nit, respectively; Fig. 2, E and F]. Al. The level of cFos immunoreactivity was undetectable after saline and minimal in responseto Nit 5 + 2 and 5 + 0.7 cFos-positive cells in responseto 0.05 and 0.1 mg kg Nit, respectively; photomicrographs not shown the responseto the higher dose was significant P 0.05 us. saline ; . LC. There was no significant difference between the number of cFos-positive cells in response to saline 4 & 3 cells; Fig. 3A ; and that in responseto 0.05 mg kg Nit 6 f 3 cells; Fig. Body mass in rats 52 ; , and decreased food intake in fat-tailed dunnarts [Sminthopsis crassicaudata 53 ; ] and goldfish [Carassius auratus 54 ; ]. Hypersecretion of CRF may also be responsible for weight loss in anorexia nervosa 44 ; . Additionally, stress also inhibits secretion of growth hormone in rats 41 ; , perhaps through the action of CRF neurons. Central administration of CRF in rats decreased growth hormone secretion in a dose-dependent manner 55 ; , and stress-induced decreases in plasma growth hormone concentrations are blocked by pretreatment with the CRF antagonist, -helical CRF9-41 56 ; . It is also possible that voluntary wheel running and maybe voluntary home-cage activity ; is causally related to both elevated corticosterone and reduced growth through separate pathways. Clearly the HPA axis responds acutely to exercise and causes elevated plasma corticosterone levels. Suppression of growth in exercising animals could result from limited energy availablility, or through alterations in hormone pathways other than the HPA axis. Energy deficits from insufficient food or forced exercise can result in reduced body mass 32 ; . In rats, daily voluntary running reduced fat, protein, and body mass in young males but not females ; , possibly through the involvement of gonadal hormones 57 ; . Obviously, level of running and selection history are confounded in our study, and we are prevented from any substantive discussion of the relationships of wheel running, corticosterone, and growth. Experimental studies, perhaps with adrenalectomized animals or with manipulation of CRH levels, will be required to elucidate this interesting finding!

Seven major families of 5-HT receptors have been identied, all of which have distinct pharmacological properties, regional distributions and physiological functions. Most of these receptors have several subtypes e.g. 5-HT2A, 5-HT2B, 5-HT2C ; .2 The physiological effects of 5-HT are mediated by at least four groups of 5-HT receptors, which have been distin.